Jamaican cuisine

Indulge your Taste buds - Grand Opening of Tropix Pots Cuisines Bar & Grill

Retrieved on: 
Tuesday, November 28, 2023
Jamaican cuisine, Friends, Multimedia, Spice, Jerk (cooking), Taste, Culture, Atmosphere, Restaurant

FREDERICK, Md., Nov. 28, 2023 /PRNewswire-PRWeb/ -- A newly opened restaurant and bar is a vibrant celebration of Jamaican flavors and hospitality. Tropix Pots Cuisines Bar & Grill is nestled on the city line of Frederick, and located at 490 Prospect Blvd Unit B\O. You are invited to immerse yourself in the rich tapestry of Caribbean cuisines. From the rhythmic beats of reggae in the air to the aromatic fusion of spices in the dishes, Tropix Pots Cuisines is home to authentic island foods.

Key Points: 
  • Tropix Pots Cuisines Bar & Grill is nestled on the city line of Frederick, and located at 490 Prospect Blvd Unit B\O.
  • At Tropix Pots Cuisines Bar & Grill customers can expect an exquisite fusion of traditional Jamaican recipes and contemporary culinary flair.
  • The ambiance at Tropix Pots Cuisines Bar & Grill is a testament of the island's laid-back charm, with tropical accents and welcoming atmosphere.
  • Tropix Pots Cuisines Bar & Grill located at 490 Prospect Blvd, Frederick MD 21701, is the newest destination for authentic Jamaican Cuisines.

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

Retrieved on: 
Saturday, September 4, 2021
Legal, Professional Services, Agriculture, Surnames, Food and drink, Staple foods, Tubers, Caribbean cuisine, Cassava, Crops, Jamaican cuisine, Kessler, Class action

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) (Cassava) on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the Class Period).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) (Cassava) on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the Class Period).
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Cassava Sciences Reports Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Agriculture, Food and drink, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tropical agriculture, Tubers

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the second quarter ended June 30, 2021.
  • Net cash use for operations for full-year 2021 is expected to be approximately $20 to $25 million, consistent with previous financial guidance.
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.
  • Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimers disease with a simple blood test.

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Agriculture, Food and drink, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tropical agriculture, Tubers

Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.

Key Points: 
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.
  • The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021.
  • Cassava Sciences mission is to discover and develop innovations for chronic, neurodegenerative conditions.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

Retrieved on: 
Thursday, June 17, 2021
Agriculture, Biofuels, Caribbean cuisine, Cassava, Jamaican cuisine, Tropical agriculture, Tubers, Food and drink, Branches of biology

AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.

Key Points: 
  • AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22nd at 3:20pm Eastern time.
  • Cassava Sciences mission is to discover and develop innovations for chronic, neurodegenerative conditions.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.

Reed’s® Craft Ginger Beer Expands into 1,600 Walmart Mixer Sets Nationwide

Retrieved on: 
Thursday, May 27, 2021
Drinks, Food and drink, Soft drinks, Ginger soda, Cuisine of the Ionian Islands, Ginger beer, Jamaican cuisine, Reed's, Ginger, Ginger ale

Reeds Inc. (NASDAQ: REED), makers of Americas #1 Ginger Beer, today announced the launch of its flagship Extra Ginger Beer in 12 oz.

Key Points: 
  • Reeds Inc. (NASDAQ: REED), makers of Americas #1 Ginger Beer, today announced the launch of its flagship Extra Ginger Beer in 12 oz.
  • cans led by the expansion into over 1,600 Walmart Mixer Sets, marking a secondary shelf placement for Reeds.
  • As the leading ginger beverage brand in the Unites States for over 30 years, Reeds all-natural Ginger Beer is crafted with REAL fresh organic ginger in a Jamaican-inspired recipe.
  • Established in 1989, Reed's is America's number 1 name in Ginger and Americas best-selling Ginger Beer brand and innovator for decades.

Global Cassava Processing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021
Other Manufacturing, Manufacturing, Agriculture, Crops, Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Branches of biology, Food and drink

The "Cassava Processing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cassava Processing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's latest report the global cassava processing market reached a volume of 298.8 Million Tons in 2020.
  • Looking forward, the publisher expects the global cassava processing market to exhibit moderate growth during the next five years.
  • The report has also analysed the key global players operating in the cassava processing market.

TKO Farms Graviola Now Ripe for New Markets

Retrieved on: 
Wednesday, March 31, 2021
Plants, Annona, Flora of Brazil, Hawaiian cuisine, Jamaican cuisine, Soursop, TKO, Teak, Foundation for Ancient Research and Mormon Studies, Mormonism

"Under our careful stewardship for the past five years, what is now TKO Farms has been lovingly and sustainably expanded beyond teak and mahogany trees to now be the world's largest graviola producer"

Key Points: 
  • "Under our careful stewardship for the past five years, what is now TKO Farms has been lovingly and sustainably expanded beyond teak and mahogany trees to now be the world's largest graviola producer"
    To date, TKO Farms has also built three stunning, fully-furnished cottage retreats on the farm.
  • Cottages provide a complete immersion into Belize and its culture, into TKO Farms operations, and serve as a way for TKO Farms to directly share the magic, beauty, and their work with invited guests.
  • "We recognized in graviola the next potentially transformational health and wellness ingredient," said Ken Owen, Chairman of TKO Farms.
  • Beyond its existing staple crops, TKO Farms is expanding its cultivation and processing of antioxidant-rich leaves from the graviola tree, and premium cacao.

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 23, 2021
Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Tropical agriculture, Plants, Branches of biology, Cuisine

AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2020 and provided business updates.

Key Points: 
  • AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2020 and provided business updates.
  • Cassava Sciences remains on-track to initiate two pivotal Phase 3 studies in second half of 2021.
  • Full Year 2020 Financial Results: Net loss in full-year 2020 was $6.3 million, or $0.24 per share, compared to a net loss in 2019 of $4.6 million, or $0.27 per share.
  • Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimers disease with a simple blood test.

Cassava Sciences Announces Closing of $200 Million Registered Direct Offering

Retrieved on: 
Friday, February 12, 2021
Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Registration statement, NET, Branches of biology, Plants, Agriculture

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of$49.00, for gross proceeds of approximately$200.0 million.

Key Points: 
  • AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of$49.00, for gross proceeds of approximately$200.0 million.
  • The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses.
  • Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Companys lead drug candidate for the treatment of Alzheimers disease.
  • The offering was made only by means of a prospectus supplement that forms a part of the registration statement.